Showing 1 - 4 results of 4 for search 'N. N. Shah', query time: 0.03s Refine Results
  1. 1
    P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

    P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (... by T. A. Eyre, N. N. Shah, S. Le Gouill, M. Dreyling, E. Vandenberghe, W. Jurczak, Y. Wang, C. Y. Cheah, M. Gandhi, C. Chay, J. P. Sharman, D. J. Andorsky, M. Yin, M. Balbas, J. Kherani, M. L. Wang

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY

    P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1... by L. E. Roeker, A. R. Mato, J. R. Brown, C. C. Coombs, N. N. Shah, W. G. Wierda, M. R. Patel, K. L. Lewis, M. Balbas, J. Zhao, N. C. Ku, J. F. Kherani, D. E. Tsai, B. Nair, C. Y. Cheah

    Published 2022-06-01
    Get full text
    Article
  3. 3
    S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

    S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by A. R. Mato, J. M. Pagel, C. C. Coombs, N. N. Shah, N. Lamanna, T. Munir, E. Lech-Maranda, T. A. Eyre, J. A. Woyach, W. G. Wierda, C. Y. Cheah, J. B. Cohen, L. E. Roeker, M. R. Patel, B. Fakhri, M. A. Barve, C. Tam, D. Lewis, J. N. Gerson, A. J. Alencar, C. Ujjani, I. Flinn, S. Sundaram, S. Ma, D. Jagadeesh, J. Rhodes, J. Taylor, O. Abdel-Wahab, P. Ghia, S. J. Schuster, D. Wang, B. Nair, E. Zhu, D. E. Tsai, M. S. Davids, J. R. Brown, W. Jurczak

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

    P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by T. A. Eyre, M. L. Wang, N. N. Shah, A. J. Alencar, J. N. Gerson, M. R. Patel, B. Fakhri, E. Vandenberghe, W. Jurczak, X. N. Tan, K. L. Lewis, T. Fenske, Y. Wang, C. C. Coombs, I. Flinn, D. Lewis, S. Le Gouill, M. Gandhi, C. Chay, M. L. Palomba, J. A. Woyach, J. M. Pagel, N. Lamanna, J. P. Sharman, D. J. Andorsky, J. B. Cohen, M. A. Barve, P. Ghia, M. Yin, P. L. Zinzani, C. Ujjani, Y. Koh, K. Izutsu, E. Lech-Maranda, J. Kherani, C. Tam, S. Sundaram, B. Nair, D. E. Tsai, M. Balbas, A. R. Mato, C. Y. Cheah

    Published 2022-06-01
    Get full text
    Article

Search Tools: